Yoshiya Tanaka (Shigeru Iwata, Y Tanaka)

ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 196

Top Venues

Modern rheumatology

RMD open

Annals of the rheumatic diseases

Rheumatology (Oxford, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Yoshiya Tanaka
What are the hot topics in Japanese rheumatology? Go above and beyond. RMD open 9 (1) (2023)
Yoshiya Tanaka
A review of Janus kinase inhibitors for the treatment of Covid-19 pneumonia. Inflammation and regeneration 43 (1) (2023)
Yoshiya Tanaka, Atsuko Murashima, Tatsuya Atsumi, Hiroaki Dobashi, Yohko Murakawa, Shigeki Momohara, Haruna Kawaguchi, Shinji Tanigaki, Shintaro Makino, Shigeru Saito
The management of women of child-bearing age with rheumatoid arthritis: an expert report. Expert review of clinical immunology (2023)
Tsutomu Takeuchi, Sakae Tanaka, Mitsuru Murata, Yoshiya Tanaka
Irreversible covalent Bruton's tyrosine kinase inhibitor, TAS5315 versus placebo in rheumatoid arthritis patients with inadequate response to methotrexate: a randomised, double-blind, phase IIa trial. Annals of the rheumatic diseases (2023)
Hisashi Yamanaka, Kishimoto Mitsumasa, Nobuo Nishijima, Katsuhisa Yamashita, Junnosuke Matsushima, Jacqueline O'Brien, Taylor Blachley, Melissa Eliot, Zachary Margolin, Swapna S Dave, Yoshiya Tanaka
Socioeconomic impact of treatment with biological disease-modifying antirheumatic drugs in Japanese patients with rheumatoid arthritis. Modern rheumatology (2023)
Cory Perugino, Emma L Culver, Arezou Khosroshahi, Wen Zhang, Emanuel Della-Torre, Kazuichi Okazaki, Yoshiya Tanaka, Matthias Löhr, Nicolas Schleinitz, Judith Falloon, Dewei She, Daniel Cimbora, John H Stone
Efficacy and Safety of Inebilizumab in IgG4-Related Disease: Protocol for a Randomized Controlled Trial. Rheumatology and therapy (2023)
Yasuyuki Todoroki, Yusuke Miyazaki, Yasuyuki Todoroki, Atsushi Nagayasu, Ryuichiro Kanda, Takafumi Aritomi, Satsuki Matsunaga, Masanobu Ueno, Ippei Miyagawa, Koshiro Sonomoto, Kentaro Hanami, Shingo Nakayamada, Yoshiya Tanaka
Generation-Dependent Retention Rates and Reasons for Discontinuation of Molecular Targeted Therapies in Patients with Rheumatoid Arthritis: From FIRST Registry. Rheumatology and therapy (2023)
Shingo Nakayamada, Yoshiya Tanaka
Immune Phenotype as a Biomarker for Systemic Lupus Erythematosus. Biomolecules 13 (6) (2023)
Antonis Fanouriakis, Myrto Kostopoulou, Jeanette Andersen, Martin Aringer, Laurent Arnaud, Sang-Cheol Bae, John Boletis, Ian N Bruce, Ricard Cervera, Andrea Doria, Thomas Dörner, Richard A Furie, Dafna D Gladman, Frederic A Houssiau, Luís Sousa Inês, David R W Jayne, Marios Kouloumas, László Kovács, Chi Chiu Mok, Eric F Morand, Gabriella Moroni, Marta Mosca, Johanna Mucke, Chetan B Mukhtyar, György Nagy, Sandra Navarra, Ioannis Parodis, José M Pego-Reigosa, Michelle A Petri, Bernardo A Pons-Estel, Matthias Schneider, Josef S Smolen, Elisabet Svenungsson, Yoshiya Tanaka, Maria G G Tektonidou, Y K Onno Teng, Angela Tincani, Edward M Vital, Ronald F Van Vollenhoven, Chris Wincup, George K Bertsias, Dimitrios T Boumpas
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Annals of the rheumatic diseases (2023)
Yoshiya Tanaka, Tsutomu Takeuchi, Derek Haaland, Stephen Hall, Güzide Nevsun İnanç, Zhanguo Li, Ricardo Machado Xavier, Carlos Cara, Nicola Tilt, Peter C Taylor
Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: Post-hoc analysis of clinical trials. International journal of rheumatic diseases (2023)
Peter C Taylor, Cedric Laedermann, Rieke Alten, Eugen Feist, Ernest Choy, Ewa Haladyj, Inmaculada De La Torre, Pascal Richette, Axel Finckh, Yoshiya Tanaka
A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience. Journal of clinical medicine 12 (13) (2023)
Gerd-Rüdiger R Burmester, Stanley B Cohen, Kevin L Winthrop, Peter Nash, Alan D Irvine, Atul Deodhar, Eduardo Mysler, Yoshiya Tanaka, John Liu, Ana P Lacerda, Hannah Palac, Tim Shaw, Phillip J Mease, Emma Guttman-Yassky
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD open 9 (1) (2023)
Shingo Nakayamada, Yoshiya Tanaka
Novel JAK inhibitors under investigation for systemic lupus erythematosus: - where are we now? Expert opinion on investigational drugs (2023)
Chun Wu, Yanhua Hu, Peter Schafer, Sean E Connolly, Robert Wong, Signe Holm Nielsen, Anne-Christine Bay-Jensen, Paul Emery, Yoshiya Tanaka, Vivian P Bykerk, Clifton O Bingham, Thomas Wj Huizinga, Roy M Fleischmann, Jinqi Liu
Baseline serum levels of cross-linked carboxy-terminal telopeptide of type I collagen predict abatacept treatment response in methotrexate-naive, anticitrullinated protein antibody-positive patients with early rheumatoid arthritis. RMD open 8 (2) (2023)
Yoshiya Tanaka, Fumitoshi Tago, Naoto Yamakawa, Mari Aoki, Takuya Yagi, Shizuo Akira
A new therapeutic target for systemic lupus erythematosus: the current landscape for drug development of a toll-like receptor 7/8 antagonist through academia-industry-government collaboration. Immunological medicine (2023)
Yoshiya Tanaka, Mark C Genovese, Hironori Matsushima
Long-Term Safety, Efficacy, and Patient-Centered Outcomes of Filgotinib in the Treatment of Rheumatoid Arthritis: Current Perspectives. Patient preference and adherence 17 (2023)
Shingo Nakayamada, Yoshiya Tanaka
Immune Phenotype as a Biomarker for Systemic Lupus Erythematosus. Biomolecules 13 (6) (2023)
Christina Yap, Olga Solovyeva, Johann S de Bono, Jan Rekowski, Dhrusti Patel, Thomas F Jaki, Adrian P Mander, Thomas R Jeffry Evans, Richard Wilson Peck, Kathryn S Hayward, Sally Hopewell, Moreno Ursino, Khadija Rerhou Rantell, Melanie Jane Calvert, Shing Lee, Andrew Kightley, Deborah Ashby, An-Wen Chan, Elizabeth Garrett-Mayer, John Dudley Isaacs, Robert Golub, Olga Kholmanskikh, Dawn P Richards, Oliver Boix, James Matcham, Lesley Seymour, Susan Percy Ivy, Lynley V Marshall, Antoine Hommais, Rong Liu, Yoshiya Tanaka, Jordan D Berlin, Aude Espinasse, Munyaradzi Dimairo, Christopher J Weir
Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ (Clinical research ed.) 383 (2023)
Satoshi Kubo, Shingo Nakayamada, Yoshiya Tanaka
JAK inhibitors for rheumatoid arthritis. Expert opinion on investigational drugs (2023)
Yoshiya Tanaka, Peter C Taylor, Emon Elboudwarej, Angie Hertz, Xiaorong Shao, Vladislav A Malkov, Hironori Matsushima, Kahaku Emoto, Bryan Downie, Tsutomu Takeuchi
Filgotinib Modulates Inflammation-Associated Peripheral Blood Protein Biomarkers in Adults with Active Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate. Rheumatology and therapy (2023)
Tsutomu Takeuchi, Yukihiro Chino, Masafumi Kawanishi, Megumi Nakanishi, Hirotaka Watase, Yoko Mano, Yuri Sato, Saeko Uchida, Yoshiya Tanaka
Efficacy and pharmacokinetics of ozoralizumab, an anti-TNFα NANOBODY ® compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trials. Arthritis research & therapy 25 (1) (2023)
Yoshiya Tanaka
A review of Janus kinase inhibitors for the treatment of Covid-19 pneumonia. Inflammation and regeneration 43 (1) (2023)
Akemi Tokutsu, Yosuke Okada, Akira Kurozumi, Kenichi Tanaka, Satoshi Kubo, Yoshiya Tanaka
Possible involvement of CXCR3-CXCR6 + CD4 + T cells in Langerhans cell histiocytosis. Journal of bone and mineral metabolism 41 (2) (2023)
Chun Wu, Yanhua Hu, Peter Schafer, Sean E Connolly, Robert Wong, Signe Holm Nielsen, Anne-Christine Bay-Jensen, Paul Emery, Yoshiya Tanaka, Vivian P Bykerk, Clifton O Bingham, Thomas Wj Huizinga, Roy M Fleischmann, Jinqi Liu
Baseline serum levels of cross-linked carboxy-terminal telopeptide of type I collagen predict abatacept treatment response in methotrexate-naive, anticitrullinated protein antibody-positive patients with early rheumatoid arthritis. RMD open 8 (2) (2023)
Yoshiya Tanaka, Toshiya Takahashi, Hubert van Hoogstraten, Naoto Kato, Hideto Kameda
Effect of sarilumab on unacceptable pain and inflammation control in Japanese patients with moderately-to-severely active rheumatoid arthritis: Post hoc analysis of a Phase III study (KAKEHASI). Modern rheumatology (2023)
Yuko Kaneko, Hideto Kameda, Kei Ikeda, Katsuhisa Yamashita, Ryoto Ozaki, Yoshiya Tanaka
Treatment pattern and changes in oral glucocorticoid dose after tocilizumab treatment in patients with adult Still's disease: An analysis of a Japanese claims database. International journal of rheumatic diseases (2023)
Yoshiya Tanaka, Tsutomu Takeuchi, Yoshiaki Morita, Daisuke Kato, Yuichiro Kaneko, Wataru Terada
Post hoc analysis of patients with rheumatoid arthritis (RA) under clinical remission in two Japanese phase 3 trials of peficitinib treatment (RAJ3, RAJ4). Modern rheumatology (2023)
Christina Yap, Jan Rekowski, Moreno Ursino, Olga Solovyeva, Dhrusti Patel, Munyaradzi Dimairo, Christopher J Weir, An-Wen Chan, Thomas F Jaki, Adrian P Mander, Thomas R Jeffry Evans, Richard Wilson Peck, Kathryn S Hayward, Melanie Jane Calvert, Khadija Rerhou Rantell, Shing Lee, Andrew Kightley, Sally Hopewell, Deborah Ashby, Elizabeth Garrett-Mayer, John Dudley Isaacs, Robert Golub, Olga Kholmanskikh, Dawn P Richards, Oliver Boix, James Matcham, Lesley Seymour, Susan Percy Ivy, Lynley V Marshall, Antoine Hommais, Rong Liu, Yoshiya Tanaka, Jordan D Berlin, Aude Espinasse, Johann S de Bono
Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance. BMJ (Clinical research ed.) 383 (2023)
Yasuyuki Todoroki, Yusuke Miyazaki, Koichi Amano, Kiyoshi Matsui, Hideto Kameda, Yoshino Inoue, Shingo Nakayamada, Takehisa Ogura, Yuko Kaneko, Kunihiro Yamaoka, Yoshiya Tanaka
Sustained remission following the discontinuation of tofacitinib in patients with rheumatoid arthritis (XANADU study): an open-label randomised study. RMD open 9 (2) (2023)
Yoshiya Tanaka
Viewpoint on anifrolumab in patients with systemic lupus erythematosus and a high unmet need in clinical practice. RMD open 9 (3) (2023)
Yasuyuki Todoroki, Minoru Satoh, Satoshi Kubo, Shunpei Kosaka, Shunsuke Fukuyo, Keisuke Nakatsuka, Kazuyoshi Saito, Shin Tanaka, Shingo Nakayamada, Yoshiya Tanaka
Anti-survival motor neuron complex antibodies as a novel biomarker for pulmonary arterial hypertension and interstitial lung disease in Mixed connective tissue disease. Rheumatology (Oxford, England) (2023)
Hans-Joachim Anders, Richard Furie, Ana Malvar, Ming-Hui Zhao, Keiju Hiromura, Julia Weinmann-Menke, Yulia Green, Angela Jones-Leone, Daniela Negrini, Roger A Levy, Liz Lightstone, Yoshiya Tanaka, Brad H Rovin
Effect of belimumab on kidney-related outcomes in patients with lupus nephritis: post hoc subgroup analyses of the phase 3 BLISS-LN trial. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2023)
Yoshiya Tanaka
What are the hot topics in Japanese rheumatology? Go above and beyond. RMD open 9 (1) (2023)
Aya Nawata, Shingo Nakayamada, Satoshi Hisano, Yusuke Miyazaki, Tetsu Miyamoto, Eisuke Shiba, Masanori Hisaoka, Yoshiya Tanaka
Differential expression of IFN-α, IL-12 and BAFF on renal immune cells and its relevance to disease activity and treatment responsiveness in patients with proliferative lupus nephritis. Lupus science & medicine 10 (2) (2023)
Alejandro Balsa, Siegfried Wassenberg, Yoshiya Tanaka, Anne Tournadre, Hans-Dieter Orzechowski, Vijay Rajendran, Udo Lendl, Pieter-Jan Stiers, Chris Watson, Roberto Caporali, James B Galloway, Patrick Verschueren
Effect of Filgotinib on Body Mass Index (BMI) and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in Rheumatoid Arthritis. Rheumatology and therapy (2023)
Yoshiya Tanaka
What are the hot topics in Japanese rheumatology? Go above and beyond. RMD open 9 (1) (2023)
Yoshiya Tanaka
Making a prescribing choice for rheumatoid arthritis: a focus on small molecule drugs vs. biologics for the most favourable patient outcome. Expert opinion on pharmacotherapy (2023)
Christopher T Ritchlin, Laura C Coates, Iain B McInnes, Phillip J Mease, Joseph F Merola, Yoshiya Tanaka, Akihiko Asahina, Laure Gossec, Alice B Gottlieb, Richard B Warren, Barbara Ink, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Robert B M Landewé
Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study. Annals of the rheumatic diseases (2023)
Ai Li Yeo, Rangi Kandane-Rathnayake, Rachel Koelmeyer, Vera Golder, Worawit Louthrenoo, Yi-Hsing Chen, Jiacai Cho, Aisha Lateef, Laniyati Hamijoyo, Shue-Fen Luo, Yeong-Jian J Wu, Sandra V Navarra, Leonid D Zamora, Zhan-Guo Li, Yuan An, Sargunan Sockalingam, Yasuhiro Katsumata, Masayoshi Harigai, Yanjie Hao, Zhuoli Zhang, B M D B Basnayake, Madelynn Chan, Jun Kikuchi, Tsutomu Takeuchi, Sang-Cheol Bae, Shereen Oon, Sean O'Neill, Fiona Goldblatt, Kristine Pek Ling Ng, Annie Law, Nicola Tugnet, Sunil Kumar, Cherica A Tee, Michael Lucas Tee, Naoaki Ohkubo, Yoshiya Tanaka, Wallace Chak Sing Lau, Mandana Nikpour, Alberta Y Hoi, Michelle Leech, Eric F Morand, null null
SMART-SLE: serology monitoring and repeat testing in systemic lupus erythematosus - an analysis of anti-double-stranded DNA monitoring. Rheumatology (Oxford, England) (2023)
Eric F Morand, Josef S Smolen, Michelle Petri, Yoshiya Tanaka, Maria Silk, Christina Dickson, Gabriella Meszaros, Inmaculada de la Torre, Maher Issa, Hong Zhang, Thomas Dörner
Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis. RMD open 9 (3) (2023)
Kathryn Connelly, Laura E Eades, Rachel Koelmeyer, Darshini Ayton, Vera Golder, Rangi Kandane-Rathnayake, Kate Gregory, Hermine I Brunner, Laurie Burke, Laurent Arnaud, Anca Askanase, Cynthia Aranow, Edward M Vital, Guillermo Pons-Estel, Khadija Dantata, Jeanette Andersen, Alain Cornet, Joy Buie, Ying Sun, Yoshiya Tanaka, Lee Simon, Youmna Lahoud, Alan Friedman, Kenneth Kalunian, Qing Zuraw, Victoria Werth, Sandra Garces, Eric F Morand, null null
Towards a novel clinical outcome assessment for systemic lupus erythematosus: first outcomes of an international taskforce. Nature reviews. Rheumatology (2023)
Yoshiya Tanaka, Stevan Shaw
Bimekizumab for the treatment of psoriatic arthritis. Expert review of clinical immunology (2023)
Yoshiya Tanaka, Peter C Taylor, Emon Elboudwarej, Angie Hertz, Xiaorong Shao, Vladislav A Malkov, Hironori Matsushima, Kahaku Emoto, Bryan Downie, Tsutomu Takeuchi
Correction: Filgotinib Modulates Inflammation-Associated Peripheral Blood Protein Biomarkers in Adults with Active Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate. Rheumatology and therapy (2023)
Gerd-Rüdiger R Burmester, Stanley B Cohen, Kevin L Winthrop, Peter Nash, Alan D Irvine, Atul Deodhar, Eduardo Mysler, Yoshiya Tanaka, John Liu, Ana P Lacerda, Hannah Palac, Tim Shaw, Phillip J Mease, Emma Guttman-Yassky
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD open 9 (1) (2023)
Gerd-Rüdiger R Burmester, Stanley B Cohen, Kevin L Winthrop, Peter Nash, Alan D Irvine, Atul Deodhar, Eduardo Mysler, Yoshiya Tanaka, John Liu, Ana P Lacerda, Hannah Palac, Tim Shaw, Phillip J Mease, Emma Guttman-Yassky
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD open 9 (1) (2023)
Chi Chiu Mok, Y K Onno Teng, Ramesh Saxena, Yoshiya Tanaka
Treatment of lupus nephritis: consensus, evidence and perspectives. Nature reviews. Rheumatology (2023)
Chun Wu, Yanhua Hu, Peter Schafer, Sean E Connolly, Robert Wong, Signe Holm Nielsen, Anne-Christine Bay-Jensen, Paul Emery, Yoshiya Tanaka, Vivian P Bykerk, Clifton O Bingham, Thomas Wj Huizinga, Roy M Fleischmann, Jinqi Liu
Baseline serum levels of cross-linked carboxy-terminal telopeptide of type I collagen predict abatacept treatment response in methotrexate-naive, anticitrullinated protein antibody-positive patients with early rheumatoid arthritis. RMD open 8 (2) (2023)
Akemi Tokutsu, Yosuke Okada, Akira Kurozumi, Kenichi Tanaka, Satoshi Kubo, Yoshiya Tanaka
Possible involvement of CXCR3-CXCR6 + CD4 + T cells in Langerhans cell histiocytosis. Journal of bone and mineral metabolism (2023)
Gerd-Rüdiger R Burmester, Stanley B Cohen, Kevin L Winthrop, Peter Nash, Alan D Irvine, Atul Deodhar, Eduardo Mysler, Yoshiya Tanaka, John Liu, Ana P Lacerda, Hannah Palac, Tim Shaw, Phillip J Mease, Emma Guttman-Yassky
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD open 9 (1) (2023)
Koshiro Sonomoto, Shingo Nakayamada, Yoshihisa Fujino, Hiroko Miyata, Satoshi Kubo, Yuya Fujita, Yoshino Inoue, Satsuki Matsunaga, Shigeru Iwata, Kentaro Hanami, Yasuyuki Todoroki, Hiroko Yoshinari-Korekoda, Akio Kawabe, Ayako Yamaguchi, Masanobu Ueno, Yurie Satoh-Kanda, Ryuichiro Kanda, Masashi Funada, Naoaki Ohkubo, Katsuhide Kusaka, Shumpei Kosaka, Atsushi Nagayasu, Shunsuke Fukuyo, Masao Nawata, Yusuke Miyazaki, Mikiko Tokunaga, Kenichi Tanaka, Yosuke Okada, Yoshiya Tanaka
Biological/targeted synthetic DMARDs do not arrest bone loss in patients with rheumatoid arthritis: a multicenter prospective observational study. Rheumatology (Oxford, England) (2023)
Shingo Nakayamada, Yoshiya Tanaka
Immune Phenotype as a Biomarker for Systemic Lupus Erythematosus. Biomolecules 13 (6) (2023)
Hiroko Miyata, Koshiro Sonomoto, Shunsuke Fukuyo, Shingo Nakayamada, Kazuhisa Nakano, Shigeru Iwata, Yusuke Miyazaki, Akio Kawabe, Takatoshi Aoki, Yoshiya Tanaka
Computed tomography for malignancy screening in patients with rheumatoid arthritis before initiation of disease modifying antirheumatic drug. Rheumatology (Oxford, England) (2023)
Akemi Tokutsu, Yosuke Okada, Akira Kurozumi, Kenichi Tanaka, Satoshi Kubo, Yoshiya Tanaka
Possible involvement of CXCR3-CXCR6 + CD4 + T cells in Langerhans cell histiocytosis. Journal of bone and mineral metabolism 41 (2) (2023)
Masataka Kuwana, Kazuhiko Takehara, Yoshiya Tanaka, Katsuhisa Yamashita, Kyoko Katsumata, Mai Takata, Yoshihito Shima
Efficacy and safety of tocilizumab in Japanese patients with systemic sclerosis and associated interstitial lung disease: A subgroup analysis of a global, randomised, controlled Phase 3 trial. Modern rheumatology (2023)
Yoshiya Tanaka
Ozoralizumab: first Nanobody® therapeutic for rheumatoid arthritis. Expert opinion on biological therapy (2023)
Yuya Fujita, Shigeru Iwata, Shinsuke Hidese, Sayuri Ishiwata, Satoru Ide, Hiroaki Tanaka, Koshiro Sonomoto, Yusuke Miyazaki, Shingo Nakayamada, Atsuko Ikenouchi, Kotaro Hattori, Hiroshi Kunugi, Reiji Yoshimura, Yoshiya Tanaka
Reduced homovanillic acid, SDF-1α, and SCGF-β levels in cerebrospinal fluid are related to depressive states in systemic lupus erythematosus. Rheumatology (Oxford, England) (2023)
Gerd-Rüdiger R Burmester, Stanley B Cohen, Kevin L Winthrop, Peter Nash, Alan D Irvine, Atul Deodhar, Eduardo Mysler, Yoshiya Tanaka, John Liu, Ana P Lacerda, Hannah Palac, Tim Shaw, Phillip J Mease, Emma Guttman-Yassky
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD open 9 (1) (2023)
Chun Wu, Yanhua Hu, Peter Schafer, Sean E Connolly, Robert Wong, Signe Holm Nielsen, Anne-Christine Bay-Jensen, Paul Emery, Yoshiya Tanaka, Vivian P Bykerk, Clifton O Bingham, Thomas Wj Huizinga, Roy M Fleischmann, Jinqi Liu
Baseline serum levels of cross-linked carboxy-terminal telopeptide of type I collagen predict abatacept treatment response in methotrexate-naive, anticitrullinated protein antibody-positive patients with early rheumatoid arthritis. RMD open 8 (2) (2023)
Hiroaki Tanaka, Yukinori Okada, Shingo Nakayamada, Yusuke Miyazaki, Kyuto Sonehara, Shinichi Namba, Suguru Honda, Yuya Shirai, Kenichi Yamamoto, Yasuyuki Todoroki, Katsunori Ikari, Masayoshi Harigai, Koshiro Sonomoto, Yoshiya Tanaka
Extracting immunological and clinical heterogeneity across autoimmune rheumatic diseases by cohort-wide immunophenotyping. Annals of the rheumatic diseases (2023)
Yoshiya Tanaka, Tatsuya Atsumi, Masato Okada, Tomoya Miyamura, Tomonori Ishii, Susumu Nishiyama, Ryutaro Matsumura, Atsushi Kawakami, Nobuya Hayashi, Gabriel Abreu, Sule Yavuz, Catharina Lindholm, Hussein Al-Mossawi, Tsutomu Takeuchi
The long-term safety and tolerability of anifrolumab for patients with systemic lupus erythematosus in Japan: TULIP-LTE subgroup analysis. Modern rheumatology (2023)
Yoshiya Tanaka, Tsutomu Takeuchi, Tatsuya Atsumi, Bernard G Combe, Daniel Aletaha, Toshihiko Kaise, Vijay Rajendran
Prevention of Radiographic Progression in Higher-Risk Patients with Rheumatoid Arthritis Using Filgotinib in Phase III Studies: Narrative Review of Post Hoc Analyses. Rheumatology and therapy (2023)
Yuichi Ishikawa, Kei Tokutsu, Shingo Nakayamada, Aya Kuchiba, Kiyohide Fushimi, Shinya Matsuda, Yoshiya Tanaka
Short-term effectiveness and safety of rituximab versus cyclophosphamide for life-threatening ANCA-associated vasculitis: a propensity score analysis of the real-world nationwide database. Annals of the rheumatic diseases (2023)
Sotaro Nakajima, Haruka Tsuchiya, Mineto Ota, Megumi Ogawa, Saeko Yamada, Ryochi Yoshida, Junko Maeda, Harumi Shirai, Taro Kasai, Jun Hirose, Keita Ninagawa, Yuichiro Fujieda, Takeshi Iwasaki, Yoshimi Aizaki, Hiroshi Kajiyama, Masakazu Matsushita, Eiryo Kawakami, Naoto Tamura, Toshihide Mimura, Koichiro Ohmura, Akio Morinobu, Tatsuya Atsumi, Yoshiya Tanaka, Tsutomu Takeuchi, Sakae Tanaka, Tomohisa Okamura, Keishi Fujio
Synovial Tissue Heterogeneity in Japanese Patients with Rheumatoid Arthritis Elucidated Using a Cell-Type Deconvolution Approach. Arthritis & rheumatology (Hoboken, N.J.) (2023)
Akemi Tokutsu, Yosuke Okada, Akira Kurozumi, Kenichi Tanaka, Satoshi Kubo, Yoshiya Tanaka
Possible involvement of CXCR3-CXCR6 + CD4 + T cells in Langerhans cell histiocytosis. Journal of bone and mineral metabolism 41 (2) (2023)
Yoshiya Tanaka
What are the hot topics in Japanese rheumatology? Go above and beyond. RMD open 9 (1) (2023)
Tsutomu Takeuchi, Megumi Nakanishi, Masafumi Kawanishi, Hironori Yamasaki, Yoshiya Tanaka
Effect of extended dosing interval of anti-TNF-alpha NANOBODY® compound ozoralizumab in patients with low disease activity rheumatoid arthritis. Modern rheumatology (2023)
Sae Ochi, Koshiro Sonomoto, Shingo Nakayamada, Yoshiya Tanaka
Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry. Arthritis research & therapy 24 (1) (2022)
Edward M Vital, Joan T Merrill, Eric F Morand, Richard A Furie, Ian N Bruce, Yoshiya Tanaka, Susan Manzi, Kenneth C Kalunian, Rubana N Kalyani, Katie Streicher, Gabriel Abreu, Raj Tummala
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. Annals of the rheumatic diseases 81 (7) (2022)
Yoshiya Tanaka, Tsutomu Takeuchi, Daisuke Kato, Yuichiro Kaneko, Musashi Fukuda, Hiroyuki Izutsu, Mitsuhiro Rokuda, Désirée van der Heijde
Post hoc Analysis of Clinical Characteristics of Patients with Radiographic Progression in a Japanese phase 3 trial of Peficitinib and Methotrexate Treatment (RAJ4). Modern rheumatology (2022)
Yoshiya Tanaka, Shingo Nakayamada, Kunihiro Yamaoka, Koichiro Ohmura, Shinsuke Yasuda
Rituximab in the Real-World Treatment of Lupus Nephritis: A Retrospective Cohort Study in Japan. Modern rheumatology (2022)
Yoshiya Tanaka
Subcutaneous injection of methotrexate: advantages in the treatment of rheumatoid arthritis. Modern rheumatology (2022)
Yoshiya Tanaka, Tatsuya Atsumi, Masato Okada, Tomoya Miyamura, Tomonori Ishii, Susumu Nishiyama, Ryutaro Matsumura, Nobuya Hayashi, Gabriel Abreu, Raj Tummala, Eric F Morand, Tsutomu Takeuchi
The Efficacy and Safety of Anifrolumab in Japanese Patients With Systemic Lupus Erythematosus: TULIP-2 Subanalysis. Modern rheumatology (2022)
Masao Nawata, Kazuki Someya, Shunpei Kosaka, Takafumi Aritomi, Masashi Funada, Yuya Fujita, Atsushi Nagayasu, Yoshihisa Fujino, Kazuyoshi Saito, Yoshiya Tanaka
Usefulness of Ultrasound as a Predictor of Elderly-Onset Rheumatoid Arthritis with Polymyalgia Rheumatica-Like Onset. Modern rheumatology (2022)
Roy M Fleischmann, Eduardo Mysler, Louis Bessette, Charles G Peterfy, Patrick Durez, Yoshiya Tanaka, Jerzy Swierkot, Nasser Khan, Xianwei Bu, Yihan Li, In-Ho Song
Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study. RMD open 8 (1) (2022)
Masanobu Ueno, Ippei Miyagawa, Yusuke Miyazaki, Kentaro Hanami, Shunsuke Fukuyo, Satoshi Kubo, Shingo Nakayamada, Yoshiya Tanaka
Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes. Arthritis research & therapy 24 (1) (2022)
Daniel Aletaha, Andreas Kerschbaumer, Kastriot Kastrati, Christian Dejaco, Maxime Dougados, Iain B McInnes, Naveed Sattar, Tanja Alexandra Stamm, Tsutomu Takeuchi, Michael Trauner, Désirée Mfm van der Heijde, Marieke Voshaar, Kevin L Winthrop, Angelo Ravelli, Neil Betteridge, Gerd-Rüdiger R Burmester, Johannes W J Bijlsma, Vivian Bykerk, Roberto Caporali, Ernest H S Choy, Catalin Codreanu, Bernard Combe, Mary K Crow, Maarten P T de Wit, Paul Emery, Roy M Fleischmann, Cem Gabay, Merete Lund Hetland, Kimmie L Hyrich, AnnaMaria Iagnocco, John Dudley Isaacs, Joel M Kremer, Xavier Mariette, Peter A Merkel, Eduardo F Mysler, Peter Nash, Michael T Nurmohamed, Karel Pavelka, Gyula Poor, Andrea Rubbert-Roth, Hendrik Schulze-Koops, Anja Strangfeld, Yoshiya Tanaka, Josef S Smolen
Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update. Annals of the rheumatic diseases (2022)
Yoshiya Tanaka, Ayako Yamaguchi, Toshiaki Miyamoto, Kazuhide Tanimura, Hideyuki Iwai, Yuko Kaneko, Tsutomu Takeuchi, Koichi Amano, Naoki Iwamoto, Atsushi Kawakami, Miho Murakami, Norihiro Nishimoto, Tatsuya Atsumi, Takayuki Sumida, Koichiro Ohmura, Tsuneyo Mimori, Hisashi Yamanaka, Keishi Fujio, Yoshihisa Fujino, Kazuyoshi Saito, Kazuhisa Nakano, Shintaro Hirata, Shingo Nakayamada
Selection of treatment regimens based on shared decision-making in patients with rheumatoid arthritis on remission in the FREE-J study. Rheumatology (Oxford, England) 61 (11) (2022)
Yoshiya Tanaka, Tsukasa Matsubara, Tatsuya Atsumi, Koichi Amano, Naoki Ishiguro, Eiji Sugiyama, Kunihiro Yamaoka, Bernard G Combe, Alan J Kivitz, Sang-Cheol Bae, Edward C Keystone, Peter Nash, Franziska Matzkies, Beatrix Bartok, Alena Pechonkina, Akira Kondo, Lei Ye, Ying Guo, Chantal Tasset, John S Sundy, Tsutomu Takeuchi
Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1). Modern rheumatology 32 (2) (2022)
Kathryn Connelly, Rangi Kandane-Rathnayake, Alberta Y Hoi, Worawit Louthrenoo, Laniyati Hamijoyo, Shue Fen Luo, Yeong-Jian Jan Wu, Jiacai Cho, Aisha Lateef, C S Lau, Yi-Hsing Chen, Sandra Navarra, Leonid Zamora, Zhanguo Li, Yuan An, Sargunan Sockalingam, Yanjie Hao, Zhuoli Zhang, Madelynn Chan, Yasuhiro Katsumata, Masayoshi Harigai, Shereen Oon, Sang-Cheol Bae, Sean O'Neill, Kathryn A Gibson, Bmdb Basnayake, Jun Kikuchi, Tsutomu Takeuchi, Kristine Pek Ling Ng, Nicola Tugnet, Sunil Kumar, Fiona Goldblatt, Annie Law, Michael Tee, Cherica Tee, Yoshiya Tanaka, Naoaki Ohkubo, Jin Yu Tan, Chetan S Karyekar, Mandana Nikpour, Vera Golder, Eric F Morand
Association of Modified Systemic Lupus Erythematosus Responder Index Attainment and Long-Term Clinical Outcomes: A Five-Year Prospective Study. Arthritis & rheumatology (Hoboken, N.J.) (2022)
Naoki Kimura, Takuya Kawahara, Yukari Uemura, Tatsuya Atsumi, Takayuki Sumida, Toshihde Mimura, Yasushi Kawaguchi, Hirofumi Amano, Yukiko Iwasaki, Yuko Kaneko, Toshihiro Matsui, Yoshinao Muro, Yoshitaka Imura, Takashi Kanda, Yoshiya Tanaka, Atsushi Kawakami, Masatoshi Jinnin, Tomonori Ishii, Keiju Hiromura, Yusuke Miwa, Hiroshi Nakajima, Masataka Kuwana, Yasuhiko Nishioka, Akio Morinobu, Hideto Kameda, Hitoshi Kohsaka
Branched chain amino acids in the treatment of polymyositis and dermatomyositis: a phase II/III, multi-centre, randomized controlled trial. Rheumatology (Oxford, England) 61 (11) (2022)
Naoki Ishiguro, Yoshiya Tanaka, Tsukasa Matsubara, Tatsuya Atsumi, Koichi Amano, Eiji Sugiyama, Kunihiro Yamaoka, Kevin Winthrop, Alan Kivitz, Gerd R Burmester, Jacques-Eric Gottenberg, Mark C Genovese, Franziska Matzkies, Ying Guo, Deyuan Jiang, Beatrix Bartok, Alena Pechonkina, Akira Kondo, Robin Besuyen, Tsutomu Takeuchi
Integrated Safety Analysis of Filgotinib Treatment for Rheumatoid Arthritis in Patients from Japan Over a Median of 1.5 Years. Modern rheumatology (2022)
Yoshiya Tanaka, Claire Barrett, Yuji Hirano, Kei Ikeda, Kathy Paizis, Azusa Sameshima, Irina Mountian, Priscilla Ch Wong
Management of chronic rheumatic diseases in women 18-45 years of age in Asia Pacific: insights from patient and clinician surveys. Rheumatology international (2022)
Tsutomu Takeuchi, Masafumi Kawanishi, Megumi Nakanishi, Hironori Yamasaki, Yoshiya Tanaka
Phase II/III Results of a Trial of Anti-Tumor Necrosis Factor Multivalent NANOBODY Compound Ozoralizumab in Patients With Rheumatoid Arthritis. Arthritis & rheumatology (Hoboken, N.J.) 74 (11) (2022)
Tatsuya Atsumi, Yoshiya Tanaka, Tsukasa Matsubara, Koichi Amano, Naoki Ishiguro, Eiji Sugiyama, Kunihiro Yamaoka, René Westhovens, Daniel W T Ching, Osvaldo Daniel Messina, Gerd R Burmester, Mark Genovese, Beatrix Bartok, Alena Pechonkina, Akira Kondo, Zhaoyu Yin, Qi Gong, Chantal Tasset, Tsutomu Takeuchi
Long-Term Safety and Efficacy of Filgotinib Treatment for Rheumatoid Arthritis in Japanese Patients Naïve to MTX Treatment (FINCH 3). Modern rheumatology (2022)
Ian N Bruce, Richard A Furie, Eric F Morand, Susan Manzi, Yoshiya Tanaka, Kenneth C Kalunian, Joan T Merrill, Patricia Puzio, Emmanuelle Maho, Christi Kleoudis, Marius Albulescu, Micki Hultquist, Raj Tummala
Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials. Annals of the rheumatic diseases 81 (7) (2022)
Yoshiya Tanaka, Toshiya Takahashi, Mariko Sumi, Owen Hagino, Hubert Van Hoogstraten, Christine Xu, Naoto Kato, Hideto Kameda
Immunogenicity of sarilumab and impact on safety and efficacy in Japanese patients with rheumatoid arthritis: analysis of two Phase 3 randomised clinical trials. Modern rheumatology 32 (4) (2022)
Tong Zhang, Kaoru Yamagata, Shigeru Iwata, Koshiro Sonomoto, Gulzhan Trimova, Anh Phuong Nguyen, He Hao, Yu Shan, Mai-Phuong Nguyen, Shingo Nakayamada, Yoshiya Tanaka
Epstein-Barr virus-induced gene 3 commits human mesenchymal stem cells to differentiate into chondrocytes via endoplasmic reticulum stress sensor. PloS one 17 (12) (2022)
Tong Zhang, Kaoru Yamagata, Shigeru Iwata, Koshiro Sonomoto, Gulzhan Trimova, Anh Phuong Nguyen, He Hao, Yu Shan, Mai-Phuong Nguyen, Shingo Nakayamada, Yoshiya Tanaka
Epstein-Barr virus-induced gene 3 commits human mesenchymal stem cells to differentiate into chondrocytes via endoplasmic reticulum stress sensor. PloS one 17 (12) (2022)
Tong Zhang, Kaoru Yamagata, Shigeru Iwata, Koshiro Sonomoto, Gulzhan Trimova, Anh Phuong Nguyen, He Hao, Yu Shan, Mai-Phuong Nguyen, Shingo Nakayamada, Yoshiya Tanaka
Epstein-Barr virus-induced gene 3 commits human mesenchymal stem cells to differentiate into chondrocytes via endoplasmic reticulum stress sensor. PloS one 17 (12) (2022)
Shingo Nakayamada, Yoshiya Tanaka
Pathological relevance and treatment perspective of JAK targeting in systemic lupus erythematosus. Expert review of clinical immunology 18 (3) (2022)
Nuntana Kasitanon, Laniyati Hamijoyo, Meng Tao Li, Kenji Oku, Sandra V Navarra, Yoshiya Tanaka, Chi Chiu Mok
Management of non-renal manifestations of systemic lupus erythematosus: A systematic literature review for the APLAR consensus statements. International journal of rheumatic diseases 25 (11) (2022)
Ronald F Van Vollenhoven, Kenneth C Kalunian, Thomas Dörner, Bevra H Hahn, Yoshiya Tanaka, Robert M Gordon, Cathye Shu, Kaiyin Fei, Sheng Gao, Loqmane Seridi, Patrick Gallagher, Kim Hung Lo, Pamela Berry, Qing C Zuraw
Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus. Annals of the rheumatic diseases (2022)
Tong Zhang, Kaoru Yamagata, Shigeru Iwata, Koshiro Sonomoto, Gulzhan Trimova, Anh Phuong Nguyen, He Hao, Yu Shan, Mai-Phuong Nguyen, Shingo Nakayamada, Yoshiya Tanaka
Epstein-Barr virus-induced gene 3 commits human mesenchymal stem cells to differentiate into chondrocytes via endoplasmic reticulum stress sensor. PloS one 17 (12) (2022)
Thomas Dörner, Yoshiya Tanaka, Ernst R Dow, Alisa E Koch, Maria Silk, Jorge A Ross Terres, Jonathan T Sims, Zhe Sun, Inmaculada de la Torre, Michelle A Petri
Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus. Annals of the rheumatic diseases (2022)
Keiichi Torimoto, Yosuke Okada, Shingo Nakayamada, Satoshi Kubo, Akira Kurozumi, Manabu Narisawa, Yoshiya Tanaka
Comprehensive immunophenotypic analysis reveals the pathological involvement of Th17 cells in Graves' disease. Scientific reports 12 (1) (2022)
Yoshiya Tanaka, Tsutomu Takeuchi, Daisuke Kato, Yuichiro Kaneko, Musashi Fukuda, Hiroyuki Izutsu, Mitsuhiro Rokuda
A pooled analysis of serious infections and herpes zoster-related disease in Asian patients with rheumatoid arthritis treated with peficitinib (ASP015K) over a median of 3 years. Modern rheumatology 32 (4) (2022)
Yoshiya Tanaka, Tatsuya Atsumi, Daniel Aletaha, Beatrix Bartok, Alena Pechonkina, Ling Han, Kahaku Emoto, Shungo Kano, Vijay Rajendran, Tsutomu Takeuchi
Benefit of Filgotinib, a JAK1 Preferential Inhibitor, in Rheumatoid Arthritis Patients with Previous Rapid Radiographic Progression: Post Hoc Analysis of Two Trials. Rheumatology and therapy (2022)
Yoshiya Tanaka, Tsukasa Matsubara, Koichi Hashizume, Norihito Amano, Tsutomu Takeuchi
Efficacy and safety of abatacept in biologic-naïve patients with active rheumatoid arthritis by background methotrexate dose: post hoc analysis of a randomized, placebo-controlled, phase 4 study. Modern rheumatology 32 (3) (2022)
Takashi Onaka, Kazuhisa Nakano, Yuri Uemoto, Naoto Miyakawa, Yasuyuki Otsuka, Aiko Ogura-Kato, Fumie Iwai, Yoshiya Tanaka, Akihito Yonezawa
Allogeneic stem cell transplantation for trisomy 8-positive myelodysplastic syndrome or myelodysplastic/myeloproliferative disease with refractory Behçet's disease: Case report and the review of literature. Modern rheumatology case reports 6 (2) (2022)
Yasuyuki Todoroki, Ryuichiro Kanda, Aya Nawata, Yusuke Miyazaki, Akio Kawabe, Kentaro Hanami, Keisuke Nakatsuka, Kazuyoshi Saito, Shingo Nakayamada, Yoshiya Tanaka
Eosinophilic granulomatosis with polyangiitis exhibits T cell activation and IgG4 immune response in the tissue; comparison with IgG4-related disease. RMD open 8 (1) (2022)

Yoshiya Tanaka.css-eqlu8i{font-size:small;padding-left:4px;} (Shigeru Iwata, Y Tanaka)

Publication Activity (10 Years)

Top Topics

Top Venues

Yoshiya Tanaka (Shigeru Iwata, Y Tanaka)